Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.

Liu D, Wu N, Sun H, Dong M, Guo T, Chi P, Li G, Sun D, Jin Y.

Oncotarget. 2017 Apr 6;8(35):58292-58303. doi: 10.18632/oncotarget.16869. eCollection 2017 Aug 29.

2.

In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.

Eclov RJ, Kim MJ, Smith RP, Liang X, Ahituv N, Kroetz DL.

Drug Metab Dispos. 2017 Feb;45(2):208-215. doi: 10.1124/dmd.116.072033. Epub 2016 Nov 17.

PMID:
27856528
3.

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz DL.

Pharmacogenomics J. 2016 Nov 15. doi: 10.1038/tpj.2016.75. [Epub ahead of print]

PMID:
27845419
4.

Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients.

Chen X, Chen D, Yang S, Ma R, Pan Y, Li X, Ma S.

Cancer Cell Int. 2015 Apr 19;15:43. doi: 10.1186/s12935-015-0191-3. eCollection 2015.

5.

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance.

Wang YJ, Zhang YK, Kathawala RJ, Chen ZS.

Cancers (Basel). 2014 Sep 29;6(4):1925-52. doi: 10.3390/cancers6041925. Review.

6.

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Panczyk M.

World J Gastroenterol. 2014 Aug 7;20(29):9775-827. doi: 10.3748/wjg.v20.i29.9775. Review.

7.

Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.

Noguchi K, Katayama K, Sugimoto Y.

Pharmgenomics Pers Med. 2014 Feb 5;7:53-64. doi: 10.2147/PGPM.S38295. eCollection 2014. Review.

8.

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.

Stewart CF, Tagen M, Schwartzberg LS, Blakely LJ, Tauer KW, Smiley LM.

Cancer Chemother Pharmacol. 2014 Mar;73(3):561-8. doi: 10.1007/s00280-014-2385-0. Epub 2014 Jan 22.

9.

Global tests of P-values for multifactor dimensionality reduction models in selection of optimal number of target genes.

Dai H, Bhandary M, Becker M, Leeder JS, Gaedigk R, Motsinger-Reif AA.

BioData Min. 2012 May 22;5(1):3. doi: 10.1186/1756-0381-5-3.

10.

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Natarajan K, Xie Y, Baer MR, Ross DD.

Biochem Pharmacol. 2012 Apr 15;83(8):1084-103. doi: 10.1016/j.bcp.2012.01.002. Epub 2012 Jan 11. Review.

11.

Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.

Nakanishi T, Ross DD.

Chin J Cancer. 2012 Feb;31(2):73-99. doi: 10.5732/cjc.011.10320. Epub 2011 Nov 18. Review.

12.

Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia.

Hampras SS, Sucheston L, Weiss J, Baer MR, Zirpoli G, Singh PK, Wetzler M, Chennamaneni R, Blanco JG, Ford L, Moysich KB.

Int J Mol Epidemiol Genet. 2010;1(3):201-7. Epub 2010 May 20.

13.

Pharmacogenomic discovery using cell-based models.

Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME.

Pharmacol Rev. 2009 Dec;61(4):413-29. doi: 10.1124/pr.109.001461. Review.

14.

Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation.

Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, Gow JM, Ha C, Ma B, Poon A, Johns SJ, Stryke D, Castro RA, Tahara H, Choi JH, Chen L, Picard N, Sjödin E, Roelofs MJ, Ferrin TE, Myers R, Kroetz DL, Kwok PY, Giacomini KM.

PLoS One. 2009 Sep 9;4(9):e6942. doi: 10.1371/journal.pone.0006942.

15.

Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Tahara H, Yee SW, Urban TJ, Hesselson S, Castro RA, Kawamoto M, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Giacomini KM.

J Pharmacol Exp Ther. 2009 Apr;329(1):262-71. doi: 10.1124/jpet.108.146449. Epub 2009 Jan 13.

Supplemental Content

Support Center